search button

Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis

  • Authors:
    • Fei Yuan
    • Hailong Shi
    • Jun Ji
    • Qu Cai
    • Xuehua Chen
    • Yingyan Yu
    • Bingya Liu
    • Zhenggang Zhu
    • Jun Zhang

  • View Affiliations

  • Published online on: January 29, 2015     https://doi.org/10.3892/or.2015.3765
  • Pages: 1753-1762
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the inhibitory effect and mechanism of capecitabine metronomic chemotherapy on gastric cancer cells. In vitro, the effects of 5-fluorouracil (Fu) metronomic chemotherapy on proliferation, apoptosis, tube formation ability, and angiogenesis were detected. In vivo, Ki-67, CD34 and VEGF were detected by immunohistochemical staining (IHC). Flow cytometry was used to detect the percentage of circulating endothelial progenitors (CEPs), and VEGF and PDGF were detected by ELISA in the peripheral blood of nude mice. The proliferation of the SGC-7901 and AGS gastric cancer cell lines in the metronomic 5-Fu group was decreased compared with the control group in vitro. The total length of the small tubes and tubular junction numbers were significantly lower in the metronomic group than the control group. The VEGF and PDGF levels in the cell culture supernatants were lower in the metronomic group than the control group. Compared with the control group, the CEP percentage was decreased in the peripheral blood of tumor-bearing nude mice following treatment with metronomic 5-Fu or capecitabine chemotherapy. No significant changes were found in the conventional or control group. In the peripheral blood of tumor-bearing nude mice, the VEGF and PDGF levels were decreased in the metronomic groups. Metronomic 5-Fu inhibited the proliferation of gastric cancer cells in vitro and in vivo, and their antitumor effects were non-inferior to those of conventional dose chemotherapy, with mild side effects. Thus, tumor inhibition may be attri­buted to anti-angiogenesis.
View Figures
View References

Related Articles

Journal Cover

April-2015
Volume 33 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yuan F, Shi H, Ji J, Cai Q, Chen X, Yu Y, Liu B, Zhu Z and Zhang J: Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis. Oncol Rep 33: 1753-1762, 2015.
APA
Yuan, F., Shi, H., Ji, J., Cai, Q., Chen, X., Yu, Y. ... Zhang, J. (2015). Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis. Oncology Reports, 33, 1753-1762. https://doi.org/10.3892/or.2015.3765
MLA
Yuan, F., Shi, H., Ji, J., Cai, Q., Chen, X., Yu, Y., Liu, B., Zhu, Z., Zhang, J."Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis". Oncology Reports 33.4 (2015): 1753-1762.
Chicago
Yuan, F., Shi, H., Ji, J., Cai, Q., Chen, X., Yu, Y., Liu, B., Zhu, Z., Zhang, J."Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis". Oncology Reports 33, no. 4 (2015): 1753-1762. https://doi.org/10.3892/or.2015.3765